Copeptin in hyponatremia: is there a role for this biomarker in the diagnostic workup?

Marco Baldrighi1 · Luigi Mario Castello1 · Ettore Bartoli1

Received: 24 January 2018 / Accepted: 31 January 2018 / Published online: 1 March 2018
© The Author(s) 2018. This article is an open access publication

Hyponatremia (plasma sodium concentration below 136 mEq/L) is the most common electrolyte derangement among both hospitalized [1] and emergency department (ED) patients [2], and its treatment represents a major issue both for internal medicine and emergency physicians. However, since different forms of hyponatremia demand different therapeutic approaches, a proper treatment is always the result of a correct diagnosis [3].

Volume status assessment is the first crucial step in the diagnostic and therapeutic algorithm of hyponatremia. Although history, clinical signs, and routine laboratory tests remain the most widely used diagnostic tools, they have shown poor accuracy in the definition of volume status [4]. The need for more reliable tools to assess patients’ volume-fueled, the research on biomarkers of hyponatremia with the specific intent to help the physician in the first steps of diagnosis, which usually take place in the ED. Among these, copeptin has been the most thoroughly studied.

Copeptin is a 39 amino acids glycoprotein that contains the C-terminal region of pre-pro-vasopressin. As a stable product of the cleavage of AVP precursor, copeptin is released in equimolar amounts with the hormone [5] and can thus be a surrogate marker of AVP secretion in clinical practice [6]. The plasma copeptin concentration varies with plasma osmolality and is affected by many different diseases, such as acute coronary syndrome, stroke, shock, and trauma. Endocrine has recently published various papers concerning the diagnostic role of copeptin in both posterior [7] and anterior pituitary disfunctions [8, 9].

In spite of the promising results of recent studies focused on the diagnostic and prognostic role of copeptin in the setting of acute dyspnea-related both to heart failure [10–12] and acute exacerbations of chronic obstructive pulmonary disease [10, 11, 13]; the findings in the field of hyponatremia are more controversial.

In 2009 Fenske et al. demonstrated through a prospective study a very high variability in copeptin levels of 106 hyponatremic patients, but suggested that the ratio between plasma copeptin and urinary sodium (P(copeptin)-to-U(Na+) ratio), could help distinguishing SIADH-related hyponatremia from that following either real or virtual volume depletion (hypovolemic and hypervolemic, respectively) [14]. In 2011 Nigro et al. performed a secondary analysis of three previous prospective studies and found that copeptin levels were lower in hypovolemic hyponatremia and progressively raised in euvolemic and hypervolemic patients [15].

In 2017 the same group published the results of a large prospective multicentre study involving 298 patients with severe hyponatremia (plasma sodium <125 mEq/L). Actually, copeptin levels were significantly different among the various causes of hyponatremia, but the post-hoc comparisons showed that only hyponatremia due to primary polydipsia could be effectively distinguished from hyponatremia due to other causes on the basis of copeptin cut-off. Moreover, in contrast to the results of their previous work, hypovolemic patients were found to have the highest copeptin levels. Interestingly, clinical volume status assessment showed a better performance in predicting hypovolemic hyponatremia than the biomarker [16].

Nigro et al. concluded that the diagnostic utility of copeptin is limited [16]. Our research group essentially agrees with this final statement, particularly if copeptin levels are obtained in an emergency medicine context. In fact, in the last few years we carried out many studies focused on the diagnosis and treatment of hyponatremia in the ED [17, 18]. For example, data we obtained from 22 patients with hypovolemic hyponatremia confirmed the wide variability of copeptin levels even in the same subgroup of patients (IQR 9.71–100.95 pmol/L) [18]. In the same study, we also found that only 59.1% of our
hypovolemic patients had a P(copeptin)-to-\(\text{U}(\text{Na}^+))\) ratio reported to be consistent with hypovolemia according to the cut-off value proposed by Fenske et al. [14].

Unpublished data obtained from a secondary analysis of 18 euvolemic and hypervolemic patients with hyponatremia enrolled in another ED trial [17], once again demonstrates a wide variability in copeptin levels without significant differences between euvolemic and hypervolemic patients.

In our studies, patients were divided into larger and more heterogeneous groups than those created by Nigro et al. according to a precise, definitive aetiologic diagnosis put on the basis of many elements comprehensive of the response to treatment [16]. However, we think that this better reflects what usually happens in an ED, where a causative diagnosis is mostly presumptive and patients can only be categorized according to their volume status. On the other hand, in more selected groups of patients, copeptin has shown a better diagnostic potential (for example to detect paraneoplastic SIADH in cancer patients [7]).

Concluding, we think that copeptin cannot be a useful biomarker in the initial approach to hyponatremia in the ED. The main explanation could be that copeptin levels increase in response to most of the acute as well as to stress conditions. As these both are present almost unerringly in ED patients, the regulation of AVP secretion by osmotic and non-osmotic stimuli (i.e., hypertonicity and volume depletion, respectively) can be disrupted, thus undermining the pathophysiologic rationale that underlies the use of copeptin as a biomarker in hyponatremia.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. A. Upadhyay, B.L. Jaber, N.E. Madias, Incidence and prevalence of hyponatremia. Am. J. Med. 119, 30–35 (2006)
2. G. Spasovski, R. Vanholder, B. Alloio et al., Clinical practice guideline on diagnosis and treatment of hyponatremia. Nephrol. Dial. Transplant. 29, 1–39 (2014)
3. W. Fenske, S.K. Maier, A. Blechschmidt, B. Alloio, S. Störk, Utility and limitations of the traditional diagnostic approach to hyponatremia: a diagnostic study. Am. J. Med. 123, 652–657 (2010)
4. H.M. Chung, R. Kluge, R.W. Schrier, R.J. Anderson, Clinical assessment of extracellular fluid volume in hyponatremia. Am. J. Med. 83, 905–908 (1987)
5. D.A. Holwerda, A glycopeptide from the posterior lobe of pig pituitaries. I. Isolation and characterization. Eur. J. Biochem. 28, 334–339 (1972)
6. N.G. Morgenthaler, J. Struck, S. Jochberger, M.W. Dünser, Copeptin: clinical use of a new biomarker. Trends Endocrinol. Metab. 19, 43–49 (2008)
7. A. Wutke, K.C. Dixit, G. Szinnai et al., Copeptin as a marker for arginine-vasopressin/antidiuretic hormone secretion in the diagnosis of paraneoplastic syndrome of inappropriate ADH secretion. Endocrine 44(3), 744–749 (2013)
8. K.C. Lewandowski, A. Lewiński, E. Skowrońska-Jóźwiak, M. Stasiak, W. Horzelski, G. Brabant, Copeptin under glucagon stimulation. Endocrine 52(2), 344–351 (2016)
9. K.C. Lewandowski, A. Lewiński, E. Skowrońska-Jóźwiak, K. Malicka, W. Horzelski, G. Brabant, Copeptin as a marker of an altered CRH axis in pituitary disease. Endocrine 57(3), 474–480 (2017)
10. F. Vetrone, S. Santarelli, V. Russo et al., Copeptin decrease from admission to discharge has favorable prognostic value for 90-day events in patients admitted with dyspnea. Clin. Chem. Lab. Med. 52(10), 1457–1464 (2014)
11. J.A. Winther, J. Brynildsen, A.D. Høiseth et al., Prognostic and diagnostic significance of copeptin in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 study. Respir. Res. 18(1), 184 (2017)
12. J.J. Yan, Y. Lu, Z.P. Kuai, Y.H. Yong, Predictive value of plasma copeptin level for the risk and mortality of heart failure: a meta-analysis. J. Cell. Mol. Med. 21(9), 1815–1825 (2017)
13. M. Dres, P. Hausfater, F. Foissac et al., Mid-regional pro-adrenergic peptide and copeptin to predict short-term prognosis of COPD exacerbations: a multicenter prospective blinded study. Int. J. Chron. Obstruct. Pulmon. Dis. 12, 1047–1056 (2017)
14. W. Fenske, S. Störk, A. Blechschmidt, S.G. Maier, N.G. Morgenthaler, B. Alloio, Copeptin in the differential diagnosis of hyponatremia. J. Clin. Endocrinol. Metab. 94, 123–129 (2009)
15. N. Nigro, B. Müller, N.G. Morgenthaler et al., The use of copeptin, the stable peptide of the vasopressin precursor, in the differential diagnosis of sodium imbalance in patients with acute diseases. Swiss Med. Wkly. 141, w13270 (2011)
16. N. Nigro, B. Winzeler, I. Suter-Widmer et al., Evaluation of copeptin and commonly used laboratory parameters for the differential diagnosis of profound hyponatraemia in hospitalized patients: ‘The Co-MED Study’. Clin. Endocrinol. (Oxf.) 86(3), 456–462 (2017)
17. L.M. Castello, M. Baldrighi, A. Panizza, E. Bartoli, G.C. Avanzi, Efficacy and safety of two different tolvaptan doses in the treatment of hyponatremia in the emergency department. Intern. Emerg. Med. 12(7), 993–1001 (2017)
18. L.M. Castello, M. Baldrighi, F. Settanni, G.C. Avanzi, E. Bartoli, Quantitative approach for the treatment of hypovolemic hyponatremia in the emergency department. JSM. Anat. Physiol. 2(2), 1012 (2017)